On March 25, the closing price of Jincheng Pharm (300233.SZ) was reported at 21.76 yuan, a significant increase of 3.63 yuan compared to the previous trading day's closing price of 18.13 yuan, with a percentage increase of 20.02%, hitting the limit up.
Jincheng Pharm opened at 18.75 yuan, with both the highest and closing prices reaching 21.76 yuan and the lowest price at 18.65 yuan. The total trading volume for the day was 759,700 shares, with a turnover of 1.56 billion yuan. By the closing bell, Jincheng Pharm's total market value was 8.353 billion yuan, and its circulating market value was 8.049 billion yuan.
It is worth noting that Jincheng Pharm's current stock price has reached its 52-week high of 21.76 yuan.
According to reports, Jincheng Pharm obtained the Tobacco Monopoly Production Enterprise License in July 2023. In January 2025, the company announced on the investor interaction platform that its nicotine production capacity is 200 tons per year, and monthly production tasks are arranged based on order situations. Currently, nicotine is mainly used in the new tobacco field, and the company is also gradually expanding and developing other related products.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
